Merck's Latest Inspiration Is Bolt-On Acquisition of Inspire Pharma for $430M

The troubled specialty pharma offers Merck immediate revenues in ophthalmology, while the Big Pharma waits for approval of a new drug, Saflutan, for glaucoma and ocular hypertension.